HRs of elderly male vs female patients for an event in PFS in trials and treatment arms with and without rituximab, respectively
| Trial . | HR [95% CI]* without rituximab . | HR [95% CI]* with rituximab . |
|---|---|---|
| RICOVER-604 (n = 1222) | 1.1 [0.9-1.4] (n = 612; P = .348) | 1.6 [1.2-2.2] (n = 610; P = .004) |
| Pegfilgrastim trial6 (n = 103) | 1.2 [0.4-3.3] (n = 47; P = .783) | 3.5 [1.0-12.8] (n = 56; P = .055) |
| NHL-B2 (CHOP-14)8 (n = 172) | 1.2 [0.8-1.9] (n = 172; P = .420) | - |
| RICOVER-noRTh10 (n = 164) | - | 1.5 [0.9-2.5] (n = 164; P = .196) |
| All studies CHOP-14 (n = 1661) | 1.2 [0.9-1.5] (n = 831; P = .203) | 1.6 [1.2-2.1] (n = 830; P < .001) |
| Trial . | HR [95% CI]* without rituximab . | HR [95% CI]* with rituximab . |
|---|---|---|
| RICOVER-604 (n = 1222) | 1.1 [0.9-1.4] (n = 612; P = .348) | 1.6 [1.2-2.2] (n = 610; P = .004) |
| Pegfilgrastim trial6 (n = 103) | 1.2 [0.4-3.3] (n = 47; P = .783) | 3.5 [1.0-12.8] (n = 56; P = .055) |
| NHL-B2 (CHOP-14)8 (n = 172) | 1.2 [0.8-1.9] (n = 172; P = .420) | - |
| RICOVER-noRTh10 (n = 164) | - | 1.5 [0.9-2.5] (n = 164; P = .196) |
| All studies CHOP-14 (n = 1661) | 1.2 [0.9-1.5] (n = 831; P = .203) | 1.6 [1.2-2.1] (n = 830; P < .001) |
Relative risk in multivariable analyses adjusting for the IPI risk factors (elevated LDH, stage III/IV, and >1 extralymphatic site of involvement).